Bisacodyl
This article was originally published in The Tan Sheet
Executive Summary
Data support OTC laxative ingredient's classification as Category I, FDA tells Boehringer Ingelheim in a Feb. 16 letter. The agency finds the company's carcinogenicity testing of bisacodyl on heterozygous p53 transgenic mice is "acceptable" and "no further carcinogenicity testing of bisacodyl is recommended." FDA requested further safety data on bisacodyl, senna, cascara sagrada and aloe, and tentatively reclassified them from Category I (safe and effective) to Category III (further testing needed) on June 19, 1998. Novartis Consumer Health, Madaus AG, Purdue Pharma and Reckitt & Colman have agreed to conduct a two-year safety study on senna
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning